Porto-Sinusoidal Vascular Disorder
Conditions
Brief summary
Incidence of major bleedings (will be defined according to the International Society on Thrombosis and Haemostasis [ISTH])
Detailed description
To assess the preliminary efficacy of edoxaban treatment for the prevention of splanchnic vein thrombosis (SVT) development, To assess the effects of edoxaban treatment on spleen stiffness as a surrogate of portal hypertension severity measured before and after edoxaban treatment., To assess the preliminary efficacy of edoxaban treatment for the prevention of hepatic decompensation., To assess effects of edoxaban treatment on health-related quality of life.
Interventions
Sponsors
Medical University Of Vienna
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of major bleedings (will be defined according to the International Society on Thrombosis and Haemostasis [ISTH]) | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the preliminary efficacy of edoxaban treatment for the prevention of splanchnic vein thrombosis (SVT) development, To assess the effects of edoxaban treatment on spleen stiffness as a surrogate of portal hypertension severity measured before and after edoxaban treatment., To assess the preliminary efficacy of edoxaban treatment for the prevention of hepatic decompensation., To assess effects of edoxaban treatment on health-related quality of life. | — |
Countries
Austria
Outcome results
None listed